🏥 VAERS Vaccine Data Browser

🔒 Privacy & Data Disclaimer

About This Site

This is a public data browser for the Vaccine Adverse Event Reporting System (VAERS). By using this site, you acknowledge and agree to the following:

Data Source & Accuracy

  • Public Data: All data displayed comes from the publicly available VAERS database maintained by the CDC and FDA.
  • No Verification: VAERS accepts all reports without verifying medical accuracy. Reports do not prove causation between vaccines and adverse events.
  • Anyone Can Report: Healthcare providers, patients, family members, and anyone else can submit reports to VAERS.
  • Research Purpose: This data is for transparency, research, and monitoring vaccine safety signals only.

Your Privacy

  • No Personal Data Collection: This site does not collect, store, or track any personal information about visitors.
  • No Cookies: We do not use cookies except for remembering that you've seen this disclaimer (stored locally in your browser).
  • No Analytics: We do not use Google Analytics or any other tracking services.
  • Search Privacy: Your searches and filters are not logged or stored on our servers.
  • Public Data Only: The VAERS data shown here is already public and contains no personally identifiable information.

Medical Disclaimer

  • Not Medical Advice: This tool is for informational purposes only and does not provide medical advice.
  • Consult Healthcare Providers: Always consult qualified healthcare professionals for medical decisions.
  • No Liability: We are not responsible for decisions made based on this data.

Data Interpretation

  • The presence of a report does not mean the vaccine caused the adverse event.
  • Coincidental events are often reported (e.g., a heart attack that happened to occur after vaccination).
  • Serious adverse events must be reported by law, even if unrelated to the vaccine.
  • The database is useful for detecting safety signals that require further investigation.

📖 Help & Search Guide

Column Icons Legend

💀 Death
🏥 Hospitalized
🚑 Emergency Room
♿ Disability
⚠️ Life Threatening

How to Search

💡 Search Tips:
  • Select Year: Choose a specific year OR "All Years" to search across all data
  • All Years requires filters: When searching all years, you must select at least one filter (lot number, vaccine type, outcome, etc.) for performance
  • Lot number tracking: Use "All Years" + Lot Number to track lots across multiple years
  • Combine filters: Use multiple filters together to narrow results (e.g., Age + Vaccine Type + Death)
  • VAERS ID: Search for specific report by ID number
  • Age: Enter exact age (e.g., 25) or decimal (e.g., 0.5 for 6 months)
  • State: Enter 2-letter state code (e.g., CA, NY, TX)
  • Vaccine Type: Search partial names (e.g., "COVID19", "FLU", "HPV")
  • Manufacturer: Search by company (e.g., "PFIZER", "MODERNA")
  • Lot Number: Search specific vaccine lot (works great with "All Years")
  • Symptoms: Search for any symptom keyword (e.g., "fever", "rash")
  • Death/Hospitalized: Filter to only show cases with these outcomes

Understanding the Data

  • Reports are unverified: VAERS accepts all reports without medical verification
  • Not proof of causation: A report does not mean the vaccine caused the event
  • Anyone can report: Healthcare providers, patients, and family members can submit reports
  • Multiple vaccines: One report may list multiple vaccines given at the same time
  • Blank fields: Not all fields are required, so some data may be missing

Using the Table

  • Sort columns: Click column headers (ID, Age, Sex, Date, Died) to sort
  • Expand text: Click "More" to see full narrative or symptom text
  • Navigate pages: Use pagination controls at top and bottom of table
  • Export results: Click "📥 Export CSV" to download filtered data (max 10,000 records)

💡 Frequently Asked Questions (FAQ)

What is this site?

🏥 VAERS Vaccine Data Browser is an independent, third-party data browser for publicly available VAERS (Vaccine Adverse Event Reporting System) data.

Important: This site is NOT affiliated with, endorsed by, or operated by the CDC, FDA, or any government agency. We are an independent service that makes public VAERS data easier to search and analyze.

What is VAERS?

VAERS (Vaccine Adverse Event Reporting System) is a national early warning system established in 1990 to detect possible safety problems with vaccines. It's co-managed by the CDC (Centers for Disease Control and Prevention) and FDA (Food and Drug Administration).

VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination.

Official VAERS website: vaers.hhs.gov

Is this data HIPAA compliant?

Yes, absolutely. All VAERS data displayed here is:

  • Publicly available - Published by the CDC/FDA on their official website
  • De-identified - Contains no personally identifiable information (names, addresses, contact info removed)
  • Legally accessible - Available to researchers, media, and the general public under FOIA (Freedom of Information Act)
  • Not protected health information - Once de-identified and published by the government, it's no longer covered by HIPAA restrictions

This site displays the same public data available at vaers.hhs.gov/data.

Why does this site exist?

We believe in transparency and public access to health data. While the CDC/FDA provide VAERS data, their official site:

  • Is difficult to search and filter
  • Requires downloading large CSV files and technical knowledge
  • Is not user-friendly for the average person

This independent site makes the same publicly available data easier to search, filter, and understand for researchers, journalists, healthcare workers, and concerned citizens.

Where does the data come from?

All data is downloaded directly from the official CDC/FDA VAERS website at vaers.hhs.gov/data.

The data is:

  • Publicly released by the CDC/FDA every week
  • Available as downloadable CSV files
  • Imported into this site's database for easier searching
  • Displayed exactly as provided (no modifications or filtering)

This site does not collect, modify, or add to the official VAERS data.

My vaccine lot number matches one with deaths/serious events - should I be worried?

Important context:

  • VAERS reports do NOT prove causation - A report means an event occurred after vaccination, but doesn't mean the vaccine caused it
  • Anyone can report - Reports are not verified for medical accuracy before being published
  • Coincidences happen - When millions of people get vaccinated, some will experience unrelated medical events afterward
  • Large lot numbers - Popular vaccines may have hundreds of thousands of doses from one lot number
  • More vaccinations = more reports - Lots used widely will naturally have more reports

What to do:

  • Don't panic - VAERS data requires expert analysis to interpret
  • Talk to your doctor if you have concerns
  • Check official CDC/FDA safety communications for genuine safety signals
  • Remember: billions of vaccine doses have been safely administered

Can I trust VAERS data?

VAERS is valuable but has limitations:

Strengths:

  • ✅ Early warning system for potential safety signals
  • ✅ Open and transparent - publicly accessible
  • ✅ Accepts all reports regardless of likelihood of causation
  • ✅ Monitored by CDC/FDA experts who investigate concerning patterns

Limitations:

  • ⚠️ Reports are unverified - not investigated before publication
  • ⚠️ Cannot determine if vaccine caused the event
  • ⚠️ Underreporting - not all adverse events are reported
  • ⚠️ Overreporting - coincidental events may be reported
  • ⚠️ Incomplete data - not all fields are required

Bottom line: VAERS is an important tool for safety monitoring, but individual reports should not be used as proof that a vaccine caused harm.

What are "adverse events"?

An adverse event is any undesirable health occurrence that happens after vaccination, including:

  • Common reactions: Sore arm, mild fever, fatigue (usually expected)
  • Serious events: Hospitalization, disability, life-threatening illness, death
  • Coincidental events: Medical conditions that would have occurred anyway

Important: An adverse event doesn't mean the vaccine caused it - only that it occurred after vaccination. Many reported events are coincidental or unrelated.

Why are some lot numbers listed multiple times?

This is normal and expected! A person may receive multiple doses of the same vaccine from the same lot number:

  • COVID vaccines require 2-3 doses
  • HPV, Hepatitis B, and other vaccines have multi-dose schedules
  • Each dose is recorded as a separate entry

Example: Person receives Pfizer COVID dose 1 (lot ABC123) and dose 2 (lot ABC123) - lot ABC123 appears twice in their report.

How often is this data updated?

The CDC/FDA releases new VAERS data every Friday. This site is typically updated:

  • Weekly or bi-weekly for recent data
  • Check the available years to see what data is currently loaded
  • During updates, the site may be in maintenance mode temporarily

Where can I learn more?

⚠️ DISCLAIMER: This data is from the Vaccine Adverse Event Reporting System (VAERS). Reports do not establish causation between vaccines and adverse events. Anyone can submit a report, and reports are not verified. This is raw data for transparency and research purposes only.
34,052
Total Reports (2025)
500
Deaths Reported
1,634
Hospitalizations
30
ER Visits
1,191
Disabilities
570
Life Threatening
🔄 Reset 📥 Export CSV
ID Age Sex State Date ▼ Onset Days Vaccine Manufacturer Lot # Symptoms Narrative 💀 🏥 🚑 ♿ ⚠️
2818813 6 U OK 12/31/2024 MMRV
MMRV
 MERCK & CO. INC.
MERCK & CO. INC.
 Y002099
Y002099
No adverse event, Product storage error; No adverse event, Product storage error No adverse event, Product storage error; No adverse event, Product storage error
No additional AE; HCP called to report TE on PROQUAD. HCP stated that the PROQUAD was stored in the ... No additional AE; HCP called to report TE on PROQUAD. HCP stated that the PROQUAD was stored in the refrigerator and administered to multiple patients. Original AE 02722046 filed on 12/13/2024. At the time of the original report (12/13/2024), patient information was n; This spontaneous report has been received from a health care professional, referring a 6-year-old patient of unknown gender. The patient's medical history, previous adverse drug reactions, drug allergy, concurrent conditions, and concomitant medication were not provided. On 10-DEC-2024, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) injection (strength, dose, frequency, route of administration, site of administration, and vaccination scheme were not provided; lot # Y002099 which has been verified to be a valid number, expiration date reported and validated as 09-JUL-2025) as a prophylaxis; which experienced a temperature excursion before administration (product storage error). However, no signs or symptoms were reported.; Sender's Comments: US-009507513-2412USA006216: More
2818866 22 F CA 12/31/2024 RSV
RSV
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
UNK
Exposure during pregnancy; Exposure during pregnancy, Product use issue Exposure during pregnancy; Exposure during pregnancy, Product use issue
medication given to pregnant medication given to pregnant
2816892 6 U OK 12/19/2024 MMRV
MMRV
 MERCK & CO. INC.
MERCK & CO. INC.
 Y002099
No adverse event, Product storage error; No adverse event, Product storage error No adverse event, Product storage error; No adverse event, Product storage error
No adverse event; Health care professional called to report a temperature excursion on PROQUAD, the ... No adverse event; Health care professional called to report a temperature excursion on PROQUAD, the PROQUAD was stored in the refrigerator and administered; This spontaneous report was received from an other Health Professional and refers to a 6-year-old patient of unknown gender. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies, or concomitant medications. On 09-OCT-2024, the patient was vaccinated with a dose of measles, mumps, rubella, and varicella (oka-merck) virus vaccine live (PROQUAD) injection, lot #Y002099, expiration date: 09-JUL-2025, administered for prophylaxis (strength and route of administration were not provided), that underwent a temperature excursion (TE). The reporter stated that the measles, mumps, rubella, and varicella (oka-merck) virus vaccine live (PROQUAD) was stored in the refrigerator and administered to the patient. There were no reported signs or symptoms of adverse effects. No additional adverse events This is one of several reports received from the same source.; Sender's Comments: US-009507513-2412USA005703: More
2816900 8 U OK 12/19/2024 MMRV
MMRV
 MERCK & CO. INC.
MERCK & CO. INC.
 Y002099
Y002099
No adverse event, Product storage error; No adverse event, Product storage error No adverse event, Product storage error; No adverse event, Product storage error
No reported signs/symptoms of adverse effects. No additional AE/no PQC; TE on PROQUAD; This spontane... No reported signs/symptoms of adverse effects. No additional AE/no PQC; TE on PROQUAD; This spontaneous report was received from a medical assistant referring to an 8-year-old patient of unknown gender. The patient's medical history, historical drugs, past drug reactions or allergies, concurrent conditions, and concomitant drugs were not reported. On 29-AUG-2024, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) injection (lot#: Y002099, expiration date: 09-JUL-2025; strength and dose were not provided) for prophylaxis. The administered experienced temperature excursion (TE) before (product storage error). No additional adverse events (AE) were reported (no adverse event). More
2813077 62 F NC 12/02/2024 COVID19
RSV
COVID19
RSV
 NOVAVAX
PFIZER\WYETH
UNKNOWN MANUFACTURER
PFIZER\WYETH
 6024mf016
ln5482
6024MF016
LN5482
Mobility decreased, Pain in extremity; Mobility decreased, Pain in extremity; Mo... Mobility decreased, Pain in extremity; Mobility decreased, Pain in extremity; Mobility decreased, Pain in extremity; Mobility decreased, Pain in extremity More
patient states she has limited range of motion in her arm and very painful patient states she has limited range of motion in her arm and very painful
1790073 79 F OH 10/16/2021 COVID19
COVID19
COVID19
 JANSSEN
JANSSEN
JANSSEN
 Unknown
Cerebrovascular accident; Cerebrovascular accident; Cerebrovascular accident, Va... Cerebrovascular accident; Cerebrovascular accident; Cerebrovascular accident, Vaccination complication More
STROKE; This spontaneous report received from a patient concerned an 80 year old female. The patient... STROKE; This spontaneous report received from a patient concerned an 80 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had always good cholesterol and was physically active. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, 1 total, administered on 30-MAR-2021 to left deltoid for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 24-JUN-2021, the patient experienced stroke and had weakness on the left side of body (left arm and left leg). The patient was recovering from the symptoms but it was slow and was still doing physical therapy and occupational therapy for the stroke. The patient attributed the stroke to the Janssen Covid-19 vaccine. The patient was in therapy at the hospital for 29 days. On 24-JUN-2021, the patient was admitted and discharged on 22-JUL-2021. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from stroke. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20211025160- COVID-19 VACCINE AD26.COV2.S- Stroke. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. More
✓
2820941 11 M WA 01/14/2025 TDAP
 SANOFI PASTEUR
Erythema, Induration, Pain, Skin warm Erythema, Induration, Pain, Skin warm
Redness, pain, hard skin, hot to touch Redness, pain, hard skin, hot to touch
2820943 63 F FL 01/14/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
Rash, Rash erythematous Rash, Rash erythematous
Rash under breast with small red bumps and rash on partial breast Rash under breast with small red bumps and rash on partial breast
2820482 M WI 01/13/2025 HEP
 DYNAVAX TECHNOLOGIES CORPORATION
Incomplete course of vaccination, No adverse event Incomplete course of vaccination, No adverse event
Had the First Dose of Heplisav-B in August of 2024, But Has Not Received the Second Dose Yet; Initia... Had the First Dose of Heplisav-B in August of 2024, But Has Not Received the Second Dose Yet; Initial report received on 04-Dec-2024. A pharmacist reported that a 77-year-old male received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization, but he has not received the second dose yet. No medical history or concomitant medications were reported. On 12-Aug-2024, the patient received dose 1 of a hepatitis B vaccine (HEPLISAV-B (lot number, expiration date, NDC number, route, and site not reported). The patient has not received the second dose. The patient had no other side effects. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious. More
2820483 F FL 01/13/2025 HEP
 DYNAVAX TECHNOLOGIES CORPORATION
 944920
Inappropriate schedule of product administration, No adverse event Inappropriate schedule of product administration, No adverse event
Received Heplisav-B on Nov 12th, She Came Back For Second Dose on Dec 6th Is it Too Early; Initial r... Received Heplisav-B on Nov 12th, She Came Back For Second Dose on Dec 6th Is it Too Early; Initial report received on 06-Dec-2024. A nurse reported that a 26-year-old female (race and ethnicity not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization on 12-Nov-2024 and the second dose on 06-Dec-2024. No medical history or concomitant medications were reported. On 12-Nov-2024, the patient received dose 1 of a hepatitis B vaccine, HEPLISAV-B (lot number 944920, expiration date 04-Dec-2026, and NDC number 43528-003-01) intramuscularly (site not reported). On 06-Dec-2024, 24 days after receiving the first dose, the patient received dose 2 of HEPLISAV-B (lot number 944920, expiration date 04-Dec-2026, and NDC number 43528-003-01) intramuscularly (site not reported). The patient received her second injection less than one month after the first. No adverse reactions were reported. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious. More
2820484 U 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Dysgeusia Dysgeusia
Patient had bitter taste in mouth; This non-serious case was reported by a consumer via call center ... Patient had bitter taste in mouth; This non-serious case was reported by a consumer via call center representative and described the occurrence of taste bitter in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced taste bitter (Verbatim: Patient had bitter taste in mouth). The outcome of the taste bitter was not reported. It was unknown if the reporter considered the taste bitter to be related to Shingrix. It was unknown if the company considered the taste bitter to be related to Shingrix. Additional Information: GSK Receipt Date: 18-DEC-2024 The reporter reported that patient had bitter taste in mouth after administration of Shingrix vaccine. More
2820485 U 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Rash, Rash pruritic Rash, Rash pruritic
Rash over side which itched a lot; This non-serious case was reported by a consumer via patient supp... Rash over side which itched a lot; This non-serious case was reported by a consumer via patient support programs and described the occurrence of itchy rash in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced itchy rash (Verbatim: Rash over side which itched a lot). The outcome of the itchy rash was not reported. It was unknown if the reporter considered the itchy rash to be related to Shingrix. It was unknown if the company considered the itchy rash to be related to Shingrix. Additional Information: GSK Receipt Date: 18-DEC-2024 The reporter reported that patient had rash over side which itched a lot after administration of Shingrix vaccine. More
2820486 U 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Balance disorder Balance disorder
permanently have lost my balance; This non-serious case was reported by a consumer via interactive d... permanently have lost my balance; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of loss of balance in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced loss of balance (Verbatim: permanently have lost my balance). The outcome of the loss of balance was not resolved. It was unknown if the reporter considered the loss of balance to be related to Shingrix. It was unknown if the company considered the loss of balance to be related to Shingrix. Additional Information: GSK receipt date: 04-JAN-2025 and 07-JAN-2025 This case was reported by a patient via interactive digital media. The patient reported that beware the Shingles vaccine (Shingrix), had terrible reaction. He/she had a violent reaction plus permanently had lost balance. More
2820487 75 M NJ 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
Injection site induration, Myalgia, Tenderness Injection site induration, Myalgia, Tenderness
stiffness at the injection site; bad muscle ache; sensitive to touch on certain parts of his body wh... stiffness at the injection site; bad muscle ache; sensitive to touch on certain parts of his body which was painful; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site induration in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included shingles (had shingles many years ago). On 20-NOV-2024, the patient received the 1st dose of Shingrix. In NOV-2024, less than 2 weeks after receiving Shingrix, the patient experienced injection site induration (Verbatim: stiffness at the injection site), muscle pain (Verbatim: bad muscle ache) and tenderness (Verbatim: sensitive to touch on certain parts of his body which was painful). The outcome of the injection site induration and muscle pain were resolved and the outcome of the tenderness was not resolved. It was unknown if the reporter considered the injection site induration, muscle pain and tenderness to be related to Shingrix. It was unknown if the company considered the injection site induration, muscle pain and tenderness to be related to Shingrix. Additional Information: GSK receipt date: 12-DEC-2024 The reporter was the spouse of a male patient. The reporter reported that the patient experienced sensitivity in his muscles after the 1st dose of Shingrix Vaccine. It was unknown in which arm the vaccine was administered. The lot and expiry date were unknown. The reporter stated that the vaccine was provided at a local pharmacy on November 20th, 2024. The reporter stated that the patient was sensitive to touch on certain parts of his body, and it was painful. Reporter states that the patient initially reported normal stiffness at the injection site, and a bad muscle ache. The patient reported to the caller that he had shingles many years ago and it feels like the same sensitivity pain. The reporter stated It had been 5 weeks since it started, and the sensitivity pain continued. The reporter stated even the sheets bother him. This case had been link with US2024156990, reported by the same reporter.; Sender's Comments: US-GSK-US2024156990:same reporter More
2820488 74 F NJ 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
Injection site induration, Myalgia Injection site induration, Myalgia
stiffness at the injection site; a bad muscle ache; This non-serious case was reported by a consumer... stiffness at the injection site; a bad muscle ache; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site induration in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 20-NOV-2024, the patient received the 1st dose of Shingrix (intramuscular, right arm). On 20-NOV-2024, less than a day after receiving Shingrix, the patient experienced injection site induration (Verbatim: stiffness at the injection site) and muscle pain (Verbatim: a bad muscle ache). The outcome of the injection site induration and muscle pain were resolved. It was unknown if the reporter considered the injection site induration and muscle pain to be related to Shingrix. It was unknown if the company considered the injection site induration and muscle pain to be related to Shingrix. Additional Information: GSK Receipt Date: 12-DEC-2024 The reporter reported that she was a 74 year old female patient. The patient reported on December 12th, 2024, that she received the 1st dose of Shingrix vaccine at a local pharmacy. The patient was administered the vaccine in the right arm. The lot and expiry date were unknown. Reporter stated that she initially had stiffness at the injection site and a bad muscle ache. Patient reported that her symptoms just lasted a few days and had resolved. No additional event was reported.; Sender's Comments: US-GSK-US2024156989:same reporter More
2820489 M AZ 01/13/2025 HEPAB
 GLAXOSMITHKLINE BIOLOGICALS
Inappropriate schedule of product administration Inappropriate schedule of product administration
He received the first shot 37 days ago/ Twinrix's 2nd late dose; This non-serious case was repo... He received the first shot 37 days ago/ Twinrix's 2nd late dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (1st dose received 37 days ago). On 05-NOV-2024, the patient received the 2nd dose of Twinrix. On 05-NOV-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: He received the first shot 37 days ago/ Twinrix's 2nd late dose). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-DEC-2024 Pharmacist questioned could we mix Havrix and Twinrix if so, what was the schedule. If someone got Twinrix first how long should you wait to get the Havrix. He received the first shot 37 days ago. Out of precaution an AE for Interchange of vaccines was filed but Havrix was not administered. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccinations schedule. More
2820490 10 F NY 01/13/2025 TDAP
 GLAXOSMITHKLINE BIOLOGICALS
 4799G
Product storage error Product storage error
product storage error and administration/one patient received Boostrix after it was exposed to 48.3 ... product storage error and administration/one patient received Boostrix after it was exposed to 48.3 degree F for 144 hours and also 31.2 degree F for 144 hours; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 10-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 4799G, expiry date 16-NOV-2026) for prophylaxis. On 09-DEC-2024, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: product storage error and administration/one patient received Boostrix after it was exposed to 48.3 degree F for 144 hours and also 31.2 degree F for 144 hours). The outcome of the incorrect storage of drug was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 17-DEC-2024 The patient received Boostrix after it was exposed to 48.3 degree F for 144 hours and also 31.2 degree F for 144 hours, which led to incorrect storage of vaccine.; Reporter's Comments: degree More
2820491 F OH 01/13/2025 HEPAB
 GLAXOSMITHKLINE BIOLOGICALS
 344J3
Inappropriate schedule of product administration Inappropriate schedule of product administration
Twinrix - Late second dose; This non-serious case was reported by a pharmacist via call center repre... Twinrix - Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 75-year-old female patient who received HAB (Twinrix) (batch number 344J3, expiry date 12-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 28th May 2024, batch number:344J3 and expiry date:12-SEP-2026). On 21-DEC-2024, the patient received the 2nd dose of Twinrix. On 21-DEC-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix - Late second dose). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-DEC-2024 Pharmacist mentioned that a patient received the first dose of Twinrix on 28th May 2024 and second dose was given on 21st December 2024. The reporter asked how to proceed in this situation. The reporter consented to follow up. The patient received 2nd dose of Twinrix later than the recommended schedule, which led to lengthening of vaccination schedule. More
2820492 M OH 01/13/2025 MNQ
 NOVARTIS VACCINES AND DIAGNOSTICS
Product storage error Product storage error
received a dose of Menveo 2 vial following a temperature excursion.; This non-serious case was repor... received a dose of Menveo 2 vial following a temperature excursion.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of product storage error in a male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced product storage error (Verbatim: received a dose of Menveo 2 vial following a temperature excursion.). The outcome of the product storage error was unknown. Additional Information: GSK Receipt Date: 23-DEC-2024 A practice manager called to report that they administered a dose of Menveo 2 vial that had a temperature excursion to a boy born in 2008, which led to incorrect storage of vaccine. Upon callback the healthcare professional mentioned that the Menveo vaccine was exposed to 51.3-degree F for 3 hours with no prior excursions. The reporter consented to follow up. More
2820493 20 M VA 01/13/2025 HIBV
 GLAXOSMITHKLINE BIOLOGICALS
 2R4GG
Product preparation issue Product preparation issue
instead of reconstituting the vaccine, the HCP gave only the diluent portion; instead of reconstitut... instead of reconstituting the vaccine, the HCP gave only the diluent portion; instead of reconstituting the vaccine, the HCP gave only the diluent portion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 20-year-old male patient who received Hib (Hiberix) (batch number 2R4GG, expiry date 17-MAR-2026) for prophylaxis. On 16-DEC-2024, the patient received Hiberix. On 16-DEC-2024, an unknown time after receiving Hiberix, the patient experienced inappropriate preparation of medication (Verbatim: instead of reconstituting the vaccine, the HCP gave only the diluent portion) and inappropriate dose of vaccine administered (Verbatim: instead of reconstituting the vaccine, the HCP gave only the diluent portion). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK receipt Date: 24-DEC-2024 Practice Manager stated for Hiberix, instead of reconstituting the vaccine, the healthcare professional gave only the diluent portion, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The Vaccine Administration Facility was the same as Primary Reporter. More
2820494 U OH 01/13/2025 TDAP
 GLAXOSMITHKLINE BIOLOGICALS
Product storage error Product storage error
Boostrix stored at 1) 31.9F x 46 hours and 2) 51F x 3 hours; This non-serious case was reported by a... Boostrix stored at 1) 31.9F x 46 hours and 2) 51F x 3 hours; This non-serious case was reported by a other health professional via call center representative and described the occurrence of product storage error in an unspecified number of patients who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On 15-NOV-2024, an unknown time after receiving Boostrix, the patient experienced product storage error (Verbatim: Boostrix stored at 1) 31.9F x 46 hours and 2) 51F x 3 hours). The outcome of the product storage error was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-DEC-2024 The reporter requested stability data for Boostrix stored at 1) 31.9F x 46 hours and 2) 51F x 3 hours, which led to incorrect storage of vaccine. No prior excursions were reported. Boostrix had been administered to several patients, patient demographics were unknown at time of call. The reporter thought excursion occurred around 15th November 2024. The reporter consented to follow up. More
2820495 F OR 01/13/2025 MMR
 GLAXOSMITHKLINE BIOLOGICALS
 X3M3D
Incorrect route of product administration Incorrect route of product administration
vaccine it was given IM instead of Subcue; This non-serious case was reported by a pharmacist via ca... vaccine it was given IM instead of Subcue; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a adult female patient who received MMR (Priorix) (batch number X3M3D, expiry date 01-APR-2025) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: vaccine it was given IM instead of Subcue). The outcome of the subcutaneous injection formulation administered by other route was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-DEC-2024 The reporter called to report the following that he/she had a patient that received the Priorix, the MMR vaccine it was given IM instead of Subcutaneous, did the patient need to be revaccination Subcutaneous route or be the IM be sufficient, which led to subcutaneous injection formulation administered by other route. The reporter consented to follow up. More
2820496 M CA 01/13/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 G9987
Product preparation issue Product preparation issue
Administration of liquid portion only; Administration of liquid portion only; This non-serious case ... Administration of liquid portion only; Administration of liquid portion only; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 53-year-old male patient who received Herpes zoster (Shingrix) (batch number G9987, expiry date 26-OCT-2026) for prophylaxis. On 12-DEC-2024, the patient received Shingrix. On 12-DEC-2024, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Administration of liquid portion only) and inappropriate dose of vaccine administered (Verbatim: Administration of liquid portion only). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 26-DEC-2024 Office manager called to report that a patient received the liquid portion only of shingles vaccine, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter did not consent to follow-up. The Vaccine Administration Facility was the same as Primary Reporter. More
2820497 19 F MT 01/13/2025 HEP
 GLAXOSMITHKLINE BIOLOGICALS
Product administered to patient of inappropriate age Product administered to patient of inappropriate age
Engerix-B - Adult dose to an adolescent patient; Engerix-B - Adult dose to an adolescent patient.; T... Engerix-B - Adult dose to an adolescent patient; Engerix-B - Adult dose to an adolescent patient.; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 19-year-old female patient who received HBV (Engerix B adult) for prophylaxis. On 26-DEC-2024, the patient received Engerix B adult. On 26-DEC-2024, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Engerix-B - Adult dose to an adolescent patient) and overdose (Verbatim: Engerix-B - Adult dose to an adolescent patient.). The outcome of the adult product administered to child and overdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-DEC-2024 A registered nurse reported the administration of the adult dose of Engerix-B to a 19 year-old patient, which led to adult product administered to child and overdose. The nurse asked for recommendations on this situation. The reporter could not provide patient initials nor data about the dose given (lot number, expiration date). The reporter consented to follow up. More
2820505 F 01/13/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Herpes zoster, Vaccination failure Herpes zoster, Vaccination failure
Suspected vaccination failure; She has had them twice since she took shot; This serious case was rep... Suspected vaccination failure; She has had them twice since she took shot; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: She has had them twice since she took shot). The outcome of the vaccination failure was not reported and the outcome of the shingles was not resolved. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. It was unknown if the company considered the shingles to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 01-JAN-2024 This case was reported by a consumer via interactive digital media Reporter reported that the patient (sister-in-law) never had shingles so she got shot to be safe. She has had them twice since she took shot and had them on the day of reporting. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation of shingles) is considered unrelated to GSK vaccine Shingles vaccine. More
2820507 U 01/13/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Herpes zoster, Vaccination failure Herpes zoster, Vaccination failure
Suspected vaccination failure; got the shingles the next year; This serious case was reported by a c... Suspected vaccination failure; got the shingles the next year; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got the shingles the next year). The outcome of the vaccination failure and shingles were not reported. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. It was unknown if the company considered the shingles to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 06-JAN-2025 This case was reported by a patient via interactive digital media. Reporter reported that he/she got the vaccine and got the shingles the next year. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingles vaccine. More
2820508 M NE 01/13/2025 DTAP
 GLAXOSMITHKLINE BIOLOGICALS
 9R2D7
Product administered to patient of inappropriate age, Wrong product administered Product administered to patient of inappropriate age, Wrong product administered
received a dose of Infanrix instead of a dose of Boostrix; received a dose of Infanrix instead of a ... received a dose of Infanrix instead of a dose of Boostrix; received a dose of Infanrix instead of a dose of Boostrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 80-year-old male patient who received DTPa (Infanrix) (batch number 9R2D7, expiry date 23-MAY-2025) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Infanrix and Boostrix. On an unknown date, an unknown time after receiving Infanrix and not applicable after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: received a dose of Infanrix instead of a dose of Boostrix) and inappropriate age at vaccine administration (Verbatim: received a dose of Infanrix instead of a dose of Boostrix). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 16-DEC-2024 The immunization coordinator called to report that they accidentally administered a dose of Infanrix to an adult patient instead of a dose of Boostrix which led to, wrong vaccine administered and inappropriate age at vaccine administration. The reporter had a question did the patient needs an additional dose of Infanrix or was it ok to administer a dose of Boostrix now. The reporter asked did the patient needs to wait to receive another dose. More
2820583 3 F OH 01/13/2025 FLU3
 SEQIRUS, INC.
Condition aggravated, Dyspnoea Condition aggravated, Dyspnoea
Patient developed a "gasping" noise. She will be talking then all of a sudden make a gaspi... Patient developed a "gasping" noise. She will be talking then all of a sudden make a gasping noise. I would like to note that this started last year, the exact time it started is unknown. It wasn't until July last year that we finally had her seen as it got progressively worse. Patient's grandparents said it was going on longer than what both myself and my wife noticed. We ended up having her adnoids removed, and it went away and there have been "0" incidents until she got the flu shot. Since then it is back and worse than it was ever last year. It started the same day in the evening that the flu shot was administered. Wife notitied the DR office when she was in there with her other child this came back. More
2820584 38 F MI 01/13/2025 HEPA
 MERCK & CO. INC.
Incorrect dose administered, No adverse event Incorrect dose administered, No adverse event
Incorrect does was given to pt. Pt was contacted to receive correct dose. No adverse reactions. Incorrect does was given to pt. Pt was contacted to receive correct dose. No adverse reactions.
2820585 72 F VA 01/13/2025 RSV
 GLAXOSMITHKLINE BIOLOGICALS
 5H777
Injection site erythema, Product administered at inappropriate site Injection site erythema, Product administered at inappropriate site
My injection was high up on the left arm. About 3 inches down from the injection site is a red area... My injection was high up on the left arm. About 3 inches down from the injection site is a red area about 2 x 2 inches. It doesn't hurt, is not itchy or hot. It seems to be going away today. More
2820586 14 F PA 01/13/2025 COVID19
 MODERNA
 B0002
Expired product administered Expired product administered
Vaccine given after beyond use date Vaccine given after beyond use date
2820587 16 F KS 01/13/2025 MENB
MNQ
 NOVARTIS VACCINES AND DIAGNOSTICS
NOVARTIS VACCINES AND DIAGNOSTICS
 EN939
M23G5
Product storage error; Product storage error Product storage error; Product storage error
Vaccine deemed not stable due to temperature excursion Vaccine deemed not stable due to temperature excursion
2820588 25 F FL 01/13/2025 COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
 PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
 EW0169
EW0169
EW0169
30155BA
30155BA
30155BA
Anaemia, Blood prolactin, Blood testosterone, Fatigue, Full blood count; Heavy m... Anaemia, Blood prolactin, Blood testosterone, Fatigue, Full blood count; Heavy menstrual bleeding, Increased tendency to bruise, Intermenstrual bleeding, Metabolic function test, Oligomenorrhoea; Peripheral coldness, Serum ferritin decreased, Thyroid function test; Anaemia, Blood prolactin, Blood testosterone, Fatigue, Full blood count; Heavy menstrual bleeding, Increased tendency to bruise, Intermenstrual bleeding, Metabolic function test, Oligomenorrhoea; Peripheral coldness, Serum ferritin decreased, Thyroid function test More
Started bleeding marginally about two days after the first vaccine dose, despite just completing men... Started bleeding marginally about two days after the first vaccine dose, despite just completing menstrual cycle about a week prior. Menstrual cycles had been regular for about a year at that point. The bleeding then continued for 9-10 months straight, some days heavier than others. I followed up with my endocrinologist and everything, could not be found to be related to any standing medical conditions or anything else. Since then I now suffer Chronic anemia, with low ferritin levels. I never had anemia or low ferritin levels any time prior to that. I still have to take iron daily or else the levels drop and cause severe fatigue and other problems. I bruise very easily and my hands and feet are almost always ice cold now. Due to this I actually was unable to donate bone marrow to a cancer kid after being identified as a match about a year ago. More
✓
2820589 18 F PA 01/13/2025 COVID19
 MODERNA
 B0002
Expired product administered Expired product administered
Vaccine adminstered after beyond use date Vaccine adminstered after beyond use date
2820590 3 M NE 01/13/2025 HEPA
HEPA
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
 C24b9
C24b9
Febrile convulsion, Influenza A virus test negative, Influenza B virus test nega... Febrile convulsion, Influenza A virus test negative, Influenza B virus test negative, Postictal state, Pyrexia; Respiratory viral panel, Streptococcus test negative More
Per Dr.'s note. Patient appears to have had a febrile seizure very early this morning with a po... Per Dr.'s note. Patient appears to have had a febrile seizure very early this morning with a post ictal state. He was transported by paramedics to ER where he was noted to have a high fever. He had negative strep, influenza, RSV and COVID testing per mother. Respiratory viral panel is pending. He is doing well now. Mother is continuing tylenol every 4 hours. He is allergic to ibuprofen. Recommended to call the EMS for any seizure lasting more than 5 minutes. If he has a third febrile seizure or a seizure without fever, would obtain EEG. There is no FMH of seizures in mother, but she is adopted and has incomplete family history knowledge. If he has negative respiratory viral panel at ER, would report this incident to VAERS as he had second hepatitis A vaccine less than two days prior to his seizure activity. More
2820592 0.17 F ME 01/13/2025 DTPPVHBHPB
FLU3
PNC15
RV1
 MSP VACCINE COMPANY
GLAXOSMITHKLINE BIOLOGICALS
MERCK & CO. INC.
GLAXOSMITHKLINE BIOLOGICALS
 U7907AA
A555J
Y005351
32PF3
Product administered to patient of inappropriate age; Product administered to pa... Product administered to patient of inappropriate age; Product administered to patient of inappropriate age; Product administered to patient of inappropriate age; Product administered to patient of inappropriate age More
10 Week old patient was administered an influenza vaccine, which are not indicated to give until 6 m... 10 Week old patient was administered an influenza vaccine, which are not indicated to give until 6 months of age. More
2820593 1.33 F KS 01/13/2025 DTAP
FLU3
HEPA
HIBV
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
MERCK & CO. INC.
MERCK & CO. INC.
 TX77L
J245K
Y011643
X022982
Product storage error; Product storage error; Product storage error; Product sto... Product storage error; Product storage error; Product storage error; Product storage error More
Vaccine deemed not stable due to temperature excursion Vaccine deemed not stable due to temperature excursion
2820594 60 M OK 01/13/2025 TDAP
 SANOFI PASTEUR
 U7624AA
Expired product administered Expired product administered
Vaccine was expired when administered. Expiration date was 12/6/2024. Vaccine was expired when administered. Expiration date was 12/6/2024.
2820595 90 F IA 01/13/2025 TDAP
 SANOFI PASTEUR
 U8264AA
Cough, Injection site bruising, Injection site erythema, Injection site swelling... Cough, Injection site bruising, Injection site erythema, Injection site swelling, Vomiting More
emesis following coughing with breakfast the next morning, bruising redness, and swelling noted at s... emesis following coughing with breakfast the next morning, bruising redness, and swelling noted at site of administration. no respiratory distress More
2820596 62 M OH 01/13/2025 COVID19
COVID19
 MODERNA
MODERNA
 060H21A
060H21A
Computerised tomogram head, Dizziness, Ear discomfort, Echocardiogram, Syncope; ... Computerised tomogram head, Dizziness, Ear discomfort, Echocardiogram, Syncope; Tilt table test, Ultrasound Doppler More
light headed, ears full, sincope, dizziness light headed, ears full, sincope, dizziness
2820597 0.33 M MI 01/13/2025 DTAPIPV
 GLAXOSMITHKLINE BIOLOGICALS
 T343J
No adverse event, Product administered to patient of inappropriate age No adverse event, Product administered to patient of inappropriate age
Patient has not shown any signs of adverse reactions to the vaccination. Patient has not shown any signs of adverse reactions to the vaccination.
2820598 75 F NY 01/13/2025 FLU3
 SEQIRUS, INC.
 388482
Joint range of motion decreased, Pain in extremity Joint range of motion decreased, Pain in extremity
PT REPORTS SORE ARM AND LIMITED RANGE OF MOTION CONTINUING FOR 2 MONTHS NOW. PT USING PHYSICAL THERA... PT REPORTS SORE ARM AND LIMITED RANGE OF MOTION CONTINUING FOR 2 MONTHS NOW. PT USING PHYSICAL THERAPY AND IT IS GETTING BETTER. More
2820599 1.5 M MD 01/13/2025 DTAP
 GLAXOSMITHKLINE BIOLOGICALS
 5H773
Diarrhoea, Vaccination site rash Diarrhoea, Vaccination site rash
Rash occurred at vaccine site area ( Left thigh). vaccine was given 01/07/2025. Father reported rash... Rash occurred at vaccine site area ( Left thigh). vaccine was given 01/07/2025. Father reported rash same day that improved over three days. Child was seen in office on 01-10-2025 for the rash and Diarrhea concern. More
2820600 62 F FL 01/13/2025 RSV
 GLAXOSMITHKLINE BIOLOGICALS
 255t2
Extra dose administered Extra dose administered
Records stated patient received first Arexvy vaccine on 10/21/23. Patient then received another vacc... Records stated patient received first Arexvy vaccine on 10/21/23. Patient then received another vaccine on 1/13/25. When I spoke to the patient, she stated she is unaware that she got the Arexvy back in 2023 and thought it was a pneumonia vaccine, however records states otherwise. More
2820601 17 M SC 01/13/2025 MENB
MENB
 NOVARTIS VACCINES AND DIAGNOSTICS
NOVARTIS VACCINES AND DIAGNOSTICS
 DD72H
DD72H
Cold sweat, Dizziness, Hyperhidrosis, Malaise, Pain; Pruritus, Pyrexia, Streptoc... Cold sweat, Dizziness, Hyperhidrosis, Malaise, Pain; Pruritus, Pyrexia, Streptococcus test positive More
Patient receive vaccine at 10:46am. At 12:30 started to feel poorly at school - felt feverish and ac... Patient receive vaccine at 10:46am. At 12:30 started to feel poorly at school - felt feverish and achy and like he was going to pass out. Patient curled up in fetal position and sweaty/clammy - EMS called. Low grade fever in ED. After getting fluids in ED, felt much better. Zpac rx for + Strep on ED test (had been rx'ed amox previous week). Went to bed - woke up overnight - with all over itching - esp wrists and hands. Took 2 benadryl. No difficulty breathing. Epi pen at home for tree nut allergy. More
2820602 88 F AL 01/13/2025 RSV
 GLAXOSMITHKLINE BIOLOGICALS
 52Z52
Extra dose administered, No adverse event Extra dose administered, No adverse event
Patient came in and received second dose of Arexvy after getting one in 2/2024. No issues reported b... Patient came in and received second dose of Arexvy after getting one in 2/2024. No issues reported but only one dose per lifetime is recommended at this time. More
2820603 65 M FL 01/13/2025 RSV
 GLAXOSMITHKLINE BIOLOGICALS
 52Z52
Extra dose administered, No adverse event Extra dose administered, No adverse event
Patient received Arexvy Vaccine twice (11/20/2023 and 01/07/2025). The patient came to our pharmacy ... Patient received Arexvy Vaccine twice (11/20/2023 and 01/07/2025). The patient came to our pharmacy requesting to receive the vaccine we administered and were later notified patient had already received it at store. We notified the patient who stated he experienced no side effects from the vaccine. More
2820604 16 F NE 01/13/2025 COVID19
 PFIZER\BIONTECH
 Fa7485
Blood test abnormal, Fatigue, Oligomenorrhoea, Pain, Von Willebrand's disea... Blood test abnormal, Fatigue, Oligomenorrhoea, Pain, Von Willebrand's disease More
Developed fatigue, body aches. 2 days after started menstrual bleeding that wouldn't stop. Cons... Developed fatigue, body aches. 2 days after started menstrual bleeding that wouldn't stop. Consequencely, diagnosed with Von Willebrand disease without any previous chlidhood or family history. Bled for 9 months before any semblance of control. Lifelong management required. More
✓
2820605 47 F OH 01/13/2025 FLU3
FLU3
 SANOFI PASTEUR
SANOFI PASTEUR
 U8523BA
U8523BA
Discomfort, Impaired driving ability, Inflammation, Injected limb mobility decre... Discomfort, Impaired driving ability, Inflammation, Injected limb mobility decreased, Mobility decreased; Musculoskeletal pain, Neck pain, Pain, Pain in extremity More
Pt states within the first hour after the vaccine she had unusual pain in the left arm and then it m... Pt states within the first hour after the vaccine she had unusual pain in the left arm and then it moved into the left shoulder blade. By the end of the day, she could not lift her arm. The pain was 10 out of 10. The pain was mainly in the left shoulder blade and not in the arm itself. She found it very uncomfortable to sit. The pain escalated to the neck area. Then she lost movement to her head. She could not turn her head to the left or right and it hurt to move her head forward. Her mobiltity was restricted. She contacted her physician and he revoked her driving privalges. She had to work from home because she had trouble sitting or moving and couldnt drive. She had an appt with her PCP and was told her to use heating pad, pain relief patches and biofreeze gel. She had to alernate tylenol and ibuprofen around the clock for a total of 2 weeks. Her mobiltity was restricted for at least 2 weeks but she was in pain and had limited mobility for about 4 weeks. Her doctor told her she had inflammation from the vaccine. She is not sure its from the vaccine ingredients or where it was or how it was injected. She still has some pain that comes and goes from time to time. More
2820606 11 F KS 01/13/2025 HPV9
MNQ
TDAP
 MERCK & CO. INC.
NOVARTIS VACCINES AND DIAGNOSTICS
GLAXOSMITHKLINE BIOLOGICALS
 X014788
M23G5
HA9CH
Product storage error; Product storage error; Product storage error Product storage error; Product storage error; Product storage error
Vaccine deemed not stable due to temperature excursion Vaccine deemed not stable due to temperature excursion
📋 Privacy Policy & Data Disclaimer